Genomics England is partnering with GenomOncology, LLC (GO) to utilize the GO Knowledge Management System (GO KMS) as a tool for clinical reporting enablement.

Genomics England will integrate the GO KMS as a key content driver to augment clinical reporting in the 100,000 Genomes Project’s cancer programme, coupling Genomics England curated database with the GO KMS’s data for a comprehensive clinical report comprised of the most relevant drugs, prognoses, and clinical trials.

The GO KMS enables Precision Medicine by allowing users to aggregate and analyze biomarker-based data within a ‘genomics-aware’ framework that includes a diverse set of annotations including genes, pathways, drugs, alterations, transcripts, and a disease ontology.  The platform leverages a large number of existing data sources including FDA, NCCN, and ASCO guidelines as well as providing exclusive API access to the expertly curated data of My Cancer Genome^®.  In addition, the GO KMS is designed to empower researchers and clinicians alike to build and maintain their own curated knowledge repositories.

Read the full story at PR Newswire.